Stachyflin and acetylstachyflin, produced by Stachybotrys sp. RF-7260, were found to have potent anti-influenza A virus activity. Stachyflin is a new class of hemagglutinin fusion inhibitors of influenza A virus. Several derivatives were synthesized from acetylstachyflin and subjected to preliminary examination of their structure-activity relationships. Among them, the 3-oxo and 3,8'-dioxo derivatives showed potent antiviral activity similar to stachyflin. The 3-epi derivative was four times less active than stachyflin. Modification of the 6'-hydroxy group and the C-5' position markedly diminished the antiviral activity.
Stachyflin and acetylstachyflin, produced by Stachybotrys sp. RF-7260, were found to have potent anti-influenza A virus activity. Stachyflin is a new class of hemagglutinin fusion inhibitors of influenza A virus. Several derivatives were synthesized from acetylstachyflin and subjected to preliminary examination of their structure-activity relationships. Among them, the 3-oxo and 3,8'-dioxo derivatives showed potent antiviral activity similar to stachyflin. The 3-epi derivative was four times less active than stachyflin. Modification of the 6'-hydroxy group and the C-5' position markedly diminished the antiviral activity.
We have isolated acetylstachyflin (1) and stachyflin (2) by solid-state fermentation of Stachybotrys sp. RF-72601).
They possess novel pentacyclic structures including a cisfused decalin ring as a sesquiterpene part. Stachyflin (2) showed potent antiviral activity against influenza A virus mechanism of the antiviral action of stachyflin has been
shown to be inhibition of the fusion process between the viral envelope and the host cell membrane, which is an early step in the entry of the virus into host cells2,3). This differs from those of known anti-influenza virus agents such as amantadine4) and zanamivir5). Therefore, 2 is considered to be an attractive lead compound for antiinfluenza A virus agents. Preliminary investigation of the structure-activity relationships of stachyflin using 1, the main metabolite in the solid-state fermentation broth of Stachybotrys sp. RF-7260, is reported here.
Results and Discussion

Chemistry
In the SAR study of stachyflin, we first attempted to evaluate the effect of the phenol and the phenyl moieties as shown in Scheme 1. Treatment of 1 with methyl iodide and potassium carbonate (K2CO3) gave the O-methyl derivative 3. The 6'-hydroxy group of 1 was acetylated with Ac2O in pyridine to give the acetate 4. Next, compound 1 was converted to carboxymethyl derivative 5. Reaction of 1 with Turning our attention to the 3-hydroxy group, we synthesized the 3-oxo derivative 11. Compound 9 was synthesized from 1 according to the previously described procedure1). The 3-hydroxy group of 9 was oxidized with 2.0 equivalents of Jones reagent to give compound 10.
Deprotection of 10 by catalytic hydrogenation gave 3-oxo derivative 11. Reaction of 9 with 8.0 equivalents of Jones reagent led to oxidation of both the 3-hydroxy group and the 8'-methylene carbon, and subsequent catalytic hydrogenation gave 12 as described in our previous paper1).
Oxidation of the 8'-methylene carbon of compound 8 with 2,3-dichloro-5,6-dicyanobenzoquinone and subsequent deprotection by catalytic hydrogenation gave the phthalimide derivative 13 (Scheme 2). (MDBK) cells were measured according to a method described previously2). The IC50 values of acetylstachyflin
(1), stachyflin (2) and synthetic analogues against influenza A virus (H1N1) are summarized in Table 1 . The antiviral activity of 1 was about 77 times weaker than that of 2.
Moreover, the 3-epi derivative 15 was also four times less Potassium carbonate (50mg) and ethyl bromoacetate (145mg) were added to a solution of 1 (50mg, 0.12mmol) in acetone (10ml), and the mixture was heated to reflux for 16 hours. The insoluble materials were filtered off. The filtrate was evaporated under reduced pressure, and the residue was purified by preparative TLC (n-hexaneacetone=1:1) to obtain the product (60mg). The product was dissolved in 1M NaOMe/MeOH (3ml) and heated to refluxing for 2 hours. The reaction mixture was then concentrated, and the residue was partitioned between EtOAc (3ml) and water (3ml 27.48, 29.99, 31.75, 36.96, 37.37, 42.48, 44.27, 65.08, 72.05, 83.50, 95.88, 113.21, 123.07, 131.49, 147.01, 156.40, 170.02, 170.12. Compound 6 N-Bromosuccinimide (26mg) was added to an icecooled solution of 1 (42mg, 0.10mmol) in THE (6ml), and the mixture was stirred for 3 hours. Next, 10% aqueous sodium hydrogen sulfite (2ml) was added to the reaction mixture, and the mixture was stirred for 10 minutes. The reaction mixture was partitioned between EtOAc and H2O, and the EtOAc layer was washed with water and dried over anhydrous sodium sulfate. The solvent was evaporated to
give a crude product. The crude product was purified by preparative TLC (n-hexane-acetone=1:1) to give 6 21.48, 23.03, 23.48, 24.48, 26.32, 27.82, 29.99, 32.63, 37.24, 37.66, 39.38, 42.01, 44.84, 76.23, 84.23, 94.84, 113.61, 124.84, 127.38, 146.80, 150.83, 169.74, 170.40. Compound 7 N-Chlorosuccinimide (12.3mg) was added to an icecooled solution of 1 (22mg, 0.051mmol) in THE (4ml), and the mixture was stirred for 2 hours. The reaction mixture was then stirred at room temperature for another 3 hours. Next, 10% aqueous sodium hydrogen sulfite (2ml) was added to the reaction mixture, which was then stirred for 10 minutes and partitioned between EtOAc and aqueous layers. The EtOAc layer was washed with water, dried over anhydrous sodium sulfate, and the solvent was evaporated to give a crude product. The crude product was purified by preparative TLC (n-hexane-acetone=1:1) to give 7 (7.6mg, 32%) and the starting compound 1 (14mg, 64%) 27.98, 30.10, 32.33, 37.30, 37.70, 39.41, 43.53, 44.72. 170.27, 171.93. Compound 10 Jones reagent (2mol egiuiv) was added to a solution of 9 (47mg, 0.1mmol) in acetone (4ml), and the mixture was added to the reaction mixture, and the solvent was evaporated under reduced pressure. The residue was then partitioned between EtOAc (5ml) and water (2ml 20.37, 23.94, 24.16, 27.63, 29.06, 30.20, 32.59, 33.43, 37.33, 38.70, 43.56, 47.39, 48.56, 70.26, 82.19, 97.28, 136.54, 146.67, 157.40, 172.10, 215.87 .
Compound 11
A solution of 10 (13mg) in EtOAc (1ml) was treated with 10% palladium-charcoal (14mg) under a hydrogen atmosphere for 3 hours. After the catalyst was filtered off, the filtrate was concentrated under reduced pressure to give 2,3-Dichloro-5,6-dicyanobenzoquinone (90mg) was added to a solution of 8 (50mg, 0.097mmol) in watersaturated CH2Cl2 (2ml), and the mixture was allowed to stand for 5 days at room temperature. The insoluble materials in the reaction were filtered off. The filtrate was concentrated and purified by preparative TLC (CH2Cl2-MeOH=95:5) to give an oxidation product (17mg) as a pale yellow powder. A solution of the oxidation product in EtOH (1.5ml) was treated with 10% palladium-charcoal (8mg) under a hydrogen atmosphere for 3 hours. After the catalyst was filtered off, the filtrate was concentrated under reduced pressure to give 13 (8mg, 18%) 22.60, 22.96, 23.85, 26.13, 27.22, 28.94, 31.49, 36.62, 36.77, 38.69, 44.27, 75.44, 83.57, 101.26, 107.26, 114.11, 133.39, 149.96, 162.05, 167.90, 169.03, 169.62 .
Compound 14
To a solution of 10 (16mg) in MeOH (1.5ml) was added hours. Water (0.5ml) was added to the reaction mixture, which was stirred for 0.5 hour and evaporated under reduced pressure. The residue was partitioned between EtOAc (4ml) and water (2ml). The EtOAc layer was washed with water and dried over anhydrous sodium sulfate, then the solvent was evaporated to give a crude product. This crude product was purified by preparative TLC (CH2Cl2-MeOH=10:1) to give 9 (6mg, 37%) and 14 (10mg, 62%); HR FAB-MS (m/z) 476.2793 (M+H)+ 2960, 2873, 1687, 1670, 1625, 1604, 1452, 1367 
